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Deregulated SRC/FAK signaling leads to enhanced migration and invasion in many types of tumors. In myxoid and
round cell liposarcoma (MRCLS), an adipocytic tumor characterized by the expression of the fusion oncogene FUS-
CHOP, SRC have been found as one of the most activated kinases. Here we used a cell-of-origin model of MRCLS
and an MRCLS cell line to thoroughly characterize the mechanisms of cell invasion induced by FUS-CHOP using in
vitro (3D spheroid invasion assays) and in vivo (chicken chorioallantoic membrane model) approaches. FUS-CHOP
expression activated SRC-FAK signaling and increased the invasive ability of MRCLS cells. In addition, FAK
expression was found to significantly correlate with tumor aggressiveness in sarcoma patient samples. The
involvement of SRC/FAK activation in FUS-CHOP–mediated invasion was further confirmed using the SRC inhibitor
dasatinib, the specific FAK inhibitor PF-573228, and FAK siRNA. Notably, dasatinib and PF573228 could also
efficiently block the invasion of cancer stem cell subpopulations. Downstream of SRC/FAK signaling, we found
that FUS-CHOP expression increases the levels of the RHO/ROCK downstream effector phospho-MLC2 (T18/S19)M.-C., O. E, S. T.-M., L. F.-N., and F.L.: performance of experimental procedures.
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Neoplasia Vol. 20, No. 1, 2018 FUS-CHOP Induces SRC/FAK/RHO/ROCK-Dependent Invasion Tornin et al. 45and that this activation was prevented by dasatinib or PF573228. Moreover, the ROCK inhibitor RKI-1447 was able
to completely abolish invasion in FUS-CHOP–expressing cells. These data uncover the involvement of SRC/FAK/
RHO/ROCK signaling axis in FUS-CHOP–mediated invasion, thus providing a rationale for testing inhibitors of this
pathway as potential novel antimetastatic agents for MRCLS treatment.
Neoplasia (2018) 20, 44–56Introduction
Myxoid/round cell liposarcoma (MRCLS) is characterized by the
recurrent translocations which fuse FUS (FUsed in Sarcoma; also
termed TLS, Translocated in LipoSarcoma) or, less frequently, EWS
to CHOP (C/EBP HOmologous Protein; also termed DDIT3, DNA
Damage-Inducible Transcript 3). This type of liposarcoma shows a
high tendency to recur locally or to metastasize to skeletal and
pulmonary sites [1]. In addition, FUS-CHOP expression has been
related with increased metastatic potential [2]. For MRCLS,
treatment of metastatic disease mainly relies on cytotoxic drugs
despite their limited clinical response [3]. Therefore, the study of the
mechanisms involved in metastasis development may help to provide
new therapeutic strategies to treat advanced and/or disseminated
tumors more efficiently.
Nonreceptor protein tyrosine kinases, such as the focal adhesion
kinase (FAK) and SRC proto-oncogene, are key signal transducers of
a variety of cell surface receptors, including integrins and receptor
tyrosine kinases [4–7]. Integrin stimulation induces FAK autophos-
phorylation at Y397, creating a high-affinity binding site for SRC.
This association induces the autophosphorylation of SRC at Y419
and other conformational changes that lead full SRC activation [8].
Fully activated SRC can then further activate FAK by phosphory-
lation of its C-terminal domain (Y861 and Y925) and catalytic
domain (Y576 and Y577) [5].
Deregulated activity of SRC-FAK signaling in cancer cells may lead
to abnormal activation of several members of the Rho-family of
GTPases, including RHOA/C (RHO) and RAC1, which are
well-known regulators of cell migration and have been implicated
in tumor cell invasion and metastasis [9,10]. In addition, the
concurrent activation of signaling pathways like those mediated by
PI3K-AKT, ERK, or JNK may induce prosurvival signals and the
upregulation of proteolytic proteins that may contribute to the
invasion process [4,5,9,11–15].
Tumor cells have been observed to migrate and invade as single
cells, as loosely attached cell streams, or as compact and cohesive
collectives by activating the above-mentioned signaling pathways.
The type of cell migration is determined by both intrinsic and
microenvironmental factors, such as the cell morphology, the degree
of cell-cell adhesion, the existing supracellular signaling, and the
physical properties of the microenvironment [12,16,17]. In the
collective migration modes, one or several leader cells extend
protrusions that generate traction forces and may induce proteolysis
of the surrounding matrix. As a consequence, following cells are
passively dragged behind along the migration track by cell-cell adhesion
forming cell streams, small clusters, or well-organized masses
[12,16,17]. During the invasion process, cells may switch from a
collective to an individual mode of invasion. This transition occurs
when the cell-cell and cell-extracellularmatrix interactions are weakenedand is influenced by several physical and molecular cues [12,18].
According to the type of cell movement, two main models of individual
cell invasion with different requirements for Rho GTPs and proteolytic
proteins have been described [9,12,14,19,20]. The “elongated-
mesenchymal” mode is characterized by the formation of actin-rich
protrusions at the front of the cell and is mainly driven by the
activation of RAC1-induced signaling. The “rounded-amoeboid”
movement is supported by high levels of actomyosin contractility
which is induced by RHO-induced signaling. Thus, RHO activates
the Rho-associated coiled-coil–containing protein kinases 1 and 2
(ROCK) resulting in the accumulation of the phosphorylated form
of myosin light chain 2 (MLC2) at S19 which promotes actomyosin
contractility [12]. Although better described for individual cell
invasion models, mesenchymal and amoeboid morphologies and
their associated signaling are also observed in collective cell invasion
models [21].
In accordance with the protumorigenic role of altered SRC/FAK
signaling or Rho GPase activity, these factors have been frequently
found to be overexpressed in different tumor types and correlated
with poor prognosis and increased invasive and metastatic potential
[9,22–25]. Therefore, the clinical efficacy of several inhibitors with
proved activity on SRC, like dasatinib, FAK, or ROCK, is being
tested in many other solid tumors [7,26,27].
In sarcoma, several studies reported an increased activation of SRC
in patient samples and cell lines derived from different sarcoma
subtypes [28,29]. Furthermore, the inhibition of this activity with
dasatinib reduced tumor cell growth and migration in liposarcoma,
including myxoid liposarcoma, synovial sarcoma, and bone sarcoma
cell lines [28–30]. Likewise, the expression and activation status of
FAK have been related with decreased overall survival and
metastasis-free survival and increased migration in osteosarcoma
[31]. In addition, FAK inhibition resulted in decreased invasion,
migration, and tumor growth in rhabdomyosarcoma [32]. Here, we
used our previously developed MRCLS model [33,34], as well as an
MRCLS cell line, to thoroughly characterize the mechanisms used by
FUS-CHOP to promote cell invasion. Using both in vitro and in vivo
approaches, we found that FUS-CHOP–induced invasive properties
are mediated through the activation of SRC/FAK/RHO/ROCK
signaling. These findings provide a rationale for testing inhibitors of
this route as a novel therapeutic strategy for MRCLS.Materials and Methods
Cell Types, Drugs, and Ethics Statement
Human BM-MSCs sequentially mutated with up to five oncogenic
events were generated, characterized, and cultured as previously
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myxoid liposarcoma cell line 1765-92 was donated by Dr. R
Mantovani (Università degli Studi di Milano, Italy). Tumorsphere
formation protocol was previously described [36]. Dasatinib,
PF-573228, BYL-719, and RKI-1447 were obtained from
Selleckchem, (Houston, TX) (supplemental information). All
experimental protocols have been performed in accordance with
institutional review board guidelines and were approved by the
Institutional Ethics Committee of the Hospital Universitario Central
de Asturias. All samples from human origin were obtained upon
signed informed consent.
Western Blotting
Whole cell protein extraction and Western blot analysis were
performed as previously described [36]. Antibodies used are described
in Supplemental Information. Quantification of the protein bands
(IRDye fluorescent signals) was performed using the Odyssey Fc
imaging system and the software Image Studio from LICOR
(Lincoln, NE).
Three-Dimensional Spheroid Invasion Assays
Cells were suspended in DMEM plus 5% methyl cellulose (Sigma) at
80,000 cells/ml to form cell spheroids (2000 cells/spheroid) by serial
pipetting of 25 μl into a nonadhesive Petri dish, and incubated in an
inverted position for 18 hours.Next day, each cell spheroid was transferred
to an individual well of 96-well plate and embedded into a volume of 70μl
of 3 mg/ml bovine collagen type I matrix (PureCol) from Advanced
Biomatrix (San Diego, CA) and filled with 100 μl of complete media.
Collective cell invasion was monitored using a Zeiss Cell Observer Live
Imaging microscope (Zeiss, Thornwood, NY) coupled with a CO2 and
temperature-maintenance system. Time-lapse images were acquired every
15 minutes during 24 hours using a Zeiss AxioCam MRc camera. The
invasive areawas determined by calculating the difference between the final
area (t = 24 hours) and the initial area (t = 0 hour) using image J analysis
program, and datawere normalized to the control cells. Three independent
experiments including four replicates for each condition were performed.
Cell Viability Assays
The viability of all cell lines in the presence and absence of drugs
was determined using the cell proliferation reagent WST-1 (Roche,
Mannheim, Germany) as described before [36]. Three independent
experiments were performed including triplicates for each condition.
As previously reported, no significant differences were found in the
doubling times of the cell types analyzed [35].
siRNA and shRNA
A pool of FAK-specific siRNAs (On-Target plus PTK-2 siRNA,
L-003164-00-0005) and a siGenome RiSC-Free control siRNA (siCon-
trol; D-001220-01) were from Dharmacon (Lafayette, CO). Cells were
transfectedwith 100 pmol/ml siRNAs using Lipofectamine 3000 (Thermo
Fisher) as described [36]. MSC-4H-FC cells depleted of FUS-CHOP
expressionwere generated by transductionwith lentiviral particles carrying a
CHOP-shRNA expression vector (TRCN0000368983) from Sigma (St.
Louis, MO) as previously described [33].
Patients and Immunohistochemical Analysis
The clinicopathologic features of the 82 sarcoma samples and
patients treated at the Hospital Universitario Central de Asturias and
their tumors are included in Table S2. Tumor grade was evaluated inH&E-stained preparations using the French Federation of Compre-
hensive Cancer Centers grading system [37] (further details in
Supplemental Materials and Methods). Tissue microarrays were
prepared with retrospectively collected tissue specimens (FFPE), and
immunohistochemical analysis of FAK expression was performed as
detailed in the Supplemental Materials and Methods section [24]. The
immunostaining showed a homogeneous distribution and was scored
blinded to clinical data by two independent observers as low or high
protein expression levels. The experimental results distributed among
the different clinical groups of tumors were tested for significance
employing the χ2 test (with Yates' correction, when appropriate). The
statistical analysis was carried out with the software package SPSS 19.0
(SPSS, Inc., Chicago, IL). All tests were two-sided, and values of
P b .05 were considered statistically significant.
Cell Extravasation AssayUsingChickChorioallantoicMembrane
(CAM) Model
Day 13 chick embryos were used for cell extravasation assay as
described earlier [38]. Four to 10 chick embryos were injected for
each condition, and the percentage of extravasated cells in three
different regions of each embryo was calculated. For intravascular cell
imaging, the chick embryos were injected with lectin and dextran to
label the CAM vessel walls and lumen, respectively. At t = 24 hours
post intravenous injection of cells, intravital images of extravasated
cancer cells were obtained via confocal microscopy as described [38].Results
FUS-CHOP Expression Activates SRC-FAK Signaling and
Increases the Invasive Potential
To study the ability of FUS-CHOP to alter cell signaling in
sarcoma-initiating cells, we used previously developed models in which
this fusion oncogene (MSC-4H-FC cells) or the corresponding control
vector (MSC-4H-GFP cells) was expressed in human bone marrow
MSCs (BM-MSCs), the cell-of-origin for different types of sarcomas
[39,40], pretransformed with four oncogenic events (Table S1) [34].
Opposite to MSC-4H-GFP, MSC-4H-FC cells were fully transformed
and able to generate MRCLS in vivo [33].
Previous works have found that SRC signaling is one of the most
active pathways in MRCLS [29,41]. Then, we used our MRCLS
model to study whether the expression of FUS-CHOP is directly
responsible of the activation of SRC and its signaling partner FAK.
We found that, compared to MSC-4H-GFP cells, FUS-CHOP
expression in MSC-4H-FC cells increased the phosphorylation levels
of activating residues in SRC (Y-419) and FAK (Y-397) as well as the
total protein levels of FAK (Figure 1A and Supplementary Figure S1).
The ratio between phospho-FAK (Y-397) levels and total FAK
protein showed no relevant changes in MSC-4H-GFP and
MSC-4H-FC cells, indicating that the increase of the phosphorylated
form of FAK induced by FUS-CHOP is mainly due to an
upregulation of the total form of FAK rather than by an
overactivation of the mechanisms leading to the phosphorylation of
FAK (Figure S1B). Confirming the ability of FUS-CHOP to activate
this pathway, its depletion in MSC-4H-FC cells using an shRNA
designed to target CHOP prevented SRC/FAK activation, thereby
reducing the levels of phospho-SRC (Y-419), phospho-FAK (Y-397),
and total FAK (Figure 1A and Supplementary Figure S1).
Given the suggested role of activated SRC and/or FAK in invasion
[4,5,9], we next analyzed whether FUS-CHOP–expressing
Figure 1. FUS-CHOP expression activates SRC/FAK signaling and increases invasive properties. (A) Western blotting analysis of the
indicated proteins in MSC-4H-GFP, MSC-4H-FC, and MSC-4H-FC cells depleted for FUS-CHOP expression using CHOP shRNA
(MSC-4H-FC-shCHOP cells). β-Actin levels were used as loading control. Quantification of three independent experiments is plotted in
Supplementary Figure S1. (B and C) Analysis of the invasive properties of MSC-4H-GFP, MSC-4H-FC, and MSC-4H-FC-shCHOP cells using
3D spheroid invasion assays. Representative images of the 3D invading spheroids at the indicated times of assay (B) and quantification of
the invasive area (C) are presented. Scale bars = 200 μm. (D) Representative 3D volume confocal images (60× magnification) of
MSC-4H-GFP, MSC-4H-FC cells in the intravascular space (top and middle panels, respectively), and a representative extravasated
MSC-4H-FC cell (bottom panel) post intravenous injection into the chicken embryo CAM vasculature. GFP-positive cells (green), CAM
vasculature labeled using lectin-Dylight649 (violet), and CAM vessel lumen using dextran (red) are shown. Scale bar = 5 μm. (E)
Quantification of extravasation efficiency of MSC-4H-GFP and MSC-4H-FC cell lines 24 hours postinjection. Error bars represent the
standard deviation (SD), and asterisks indicate statistically significant differences with respect to the MSC-4H-FC values (*: P b .05;
**: P b .01; two-sided Student t test).
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this purpose, we studied the ability of MRCLS spheroids to invade
3D collagen matrices, an invasion assay that takes into account both
cell-cell contact between adjacent tumor cells and the need for a 3D
supporting matrix [42]. Using live cell time-lapse microscopy, we
found that MSC-4H-FC spheroids showed highly increased invasive
properties when compared with MSC-4H-GFP spheroids. Impor-
tantly, these statistically significant differences were completely
reverted by FUS-CHOP depletion in MSC-4H-FC-shCHOP
spheroids (Figure 1, B and C and Videos S1-S3).
To validate these findings in vivo, we evaluated invasiveness
phenotypes by quantifying the rates of cancer cell extravasation in the
chorioallantoic membrane (CAM) of chicken embryos [38].
MSC-4H-GFP and MSC-4H-FC cells were intravenously injectedinto the vasculature of day 13 chicken embryos followed by
assessment of extravasation efficiency 24 hours postinjection. We
observed that both cell types were able to extravasate out of the CAM
vasculature; however, in accordance with in vitro results,
MSC-4H-FC cells showed a significant increase in the extravasation
efficiency (Figure 1, D and E).
Inhibition of SRC or FAK Activation Prevents the Invasion of
FUS-CHOP–Expressing Cells
To study whether the activation of SRC plays a role in the
increased invasive properties of MSC-4H-FC cells, we treated these
cells with dasatinib. A 24-hour treatment with low micromolar
concentrations of dasatinib efficiently inhibited SRC (Y419)
phosphorylations without affecting total protein levels of SRC
Figure 2. Inhibition of SRC prevents the invasion of FUS-CHOP–expressing cells. (A) Western blotting analysis of the indicated proteins in
MSC-4H-FC cells treated with increasing concentrations of dasatinib for 24 hours. β-Actin levels were used as loading control. Quantification
of three independent experiments is plotted in Supplementary Fig S2. (B and C) Effect of increasing concentrations of dasatinib on the
invasive properties of MSC-4H-FC cells using 3D spheroid invasion assays. Representative images of the 3D spheroids treated with the
indicated concentrations of dasatinib for 24 hours (B) and quantification of the invasive area (C) are presented. Scale bars = 200 μm. (D)
Representative 3D volume confocal image (60×magnification) ofMSC-4H-FC cells pretreatedwith 0.1 μMdasatinib for 24 hours followedby
intravenous injection into the chicken embryo CAM vasculature. GFP-positive cells (green), CAM vasculature labeled using lectin-Dylight649
(violet), and CAMvessel lumen using dextran (red) are shown. Scale bars = 5 μm. (E) Quantification of extravasation efficiency of control and
dasatinib-treated MSC-4H-FC cells 24 hours postinjection. (F) Cell viability (WST1 assay) measured after the treatment of the indicated cell
lines with increasing concentrations of dasatinib for 24 or 48 hours. Error bars represent the SD, and asterisks indicate statistically significant
differences with respect to the control values (*: P b .05; **: P b .01; one-sided Student t test).
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concentrations of dasatinib induced an increase in total FAK levels
and its autophosphorylated form [FAK (Y397)], which is not
observed with higher drug concentrations. In any case, dasatinib
efficiently inhibited SRC-dependent phosphorylation of FAK on
Y861, which is a requisite for an effective activation of this kinase
(Figure 2A and Supplementary Figure S2) [5]. In addition, the
phosphorylation/activation of AKT (S473) was also reduced upon
dasatinib treatment as efficiently as phospho-SRC (Y419) orphospho-FAK (Y861) (Figure 2A and Supplementary Figure S2).
Furthermore, concentrations of dasatinib as low as 0.1 μM completely
abolished the invasion of MSC-4H-FC spheroids into 3D collagen
matrices (Figure 2, B and C and Videos S4-S9). Similarly, 0.1 μM of
dasatinib was able to significantly inhibit cell extravasation in the in vivo
CAM model (Figure 2, D and E). This potent anti-invasive effect of
dasatinib cannot be attributed to the antiproliferative properties since
24-hour treatment with low dasatinib doses only produced a mild
cytotoxic effect. Even the higher assayed concentrations (10 μM) led to
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MSC-4H-FC cells, respectively (Figure 2F). Nonetheless, these
surviving fractions decreased to 65% and 40% after 48-hour treatment
with this inhibitor (Figure 2F).
We next studied the effect of FAK inhibition using the specific
inhibitor PF-573228. A 24-hour treatment with PF-573228 caused
an effective dose-dependent inhibition of FAK phosphorylation
(Figure 3A and Supplementary Figure S3, A and B). In addition,
phospho-AKT (S473) was completely inhibited at the higher
concentration assayed (10 μM). On the other hand, phospho-SRC
(Y419) was unaffected after the treatment. Mimicking the inhibitory
effect on FAK phosphorylation, PF-573228 induced a dose-
dependent inhibition of the invasive capability of MSC-4H-FC
spheroids (Figure 3, B and C and Videos S10-S14). In vivo, 10 μM
of PF-573228 also inhibited cell extravasation out of the CAM
vasculature (Figure 3, D and E). Interestingly, intravital imaging
revealed the release of extracellular vesicles or microparticles by
intravascular PF-573228–treated cells into the stroma [43] (Figure 3D).
Similar to that observed for dasatinib, 24-hour treatment with
PF-573228 only induced mild/moderate antiproliferative effects in
MSC-4H-GFP andMSC-4H-FC cells, although cytotoxicity increased
at 48-hour treatment (Figure 3F).
To further confirm the role of FAK in the invasive properties of
FUS-CHOP–expressing MRCLS-initiating cells, we performed
siRNA-mediated depletion of this kinase in MSC-4H-FC cells.
Western blotting analysis confirmed an efficient knockdown of both
the total and phosphorylated forms of FAK (Figure 3G and
Supplementary Figure S3C). Similar to that observed by pharmaco-
logic inhibition of FAK, phospho-AKT (S473) levels also decreased
upon FAK depletion, while SRC (Y-419) phosphorylation, instead of
being reduced, was increased (Figure 3G and Supplementary Figure
S3C). In 3D invasion assays, we found that MSC-4H-FC spheroids
generated using FAK-depleted cells were completely unable to invade
collagen matrices (Figure 3, H and I and Videos S10-S16), thus
confirming the critical role of FAK in FUS-CHOP–mediated
invasion.
As seen, phosphorylation/activation of AKT (S473) was efficiently
downregulated by dasatinib (Figure 2A), PF-573228 (Figure 3A), or
FAK-siRNA (Figure 3E). To investigate a possible role of PI3K/AKT
signaling as a downstream effector of SRC/FAK proinvasive signals,
we treated MSC-4H-FC cells with the PI3K inhibitors BYL-719. At a
concentration that prevented AKT phosphorylation (Figure S4A),
this inhibitor was not able to inhibit 3D spheroid invasion (Figure
S4B), thus suggesting that SRC/FAK proinvasive signals do not
require the activation of PI3K/AKT pathway.
Finally, we aimed to test whether the SRC/FAK inhibition could
also affect invasiveness using another MRCLS model. Therefore, we
treated the 1765-92 cell line with dasatinib or PF-573228 and
checked phospho-SRC and phospho-FAK levels as well as the ability
to invade. Consistent with our results in MSC-4H-FC cells, dasatinib
inhibited the phosphorylation of SRC (Y419) and AKT (S473), while
PF-573228 efficiently reduced the phosphorylation levels of FAK
(Y397) and AKT (S473) but not SRC (Y419) (Figure 4A and
Supplementary Figure S5). Accordingly, both inhibitors also
efficiently prevented the 3D invasive capability of this MRCLS cell
line (Figure 4, B and D and Videos S17-S20), without significantly
affecting its proliferation rate (Figure 4E).
Altogether, these results suggest that the activation of the SRC/
FAK-mediated signaling is essential to maintain the invasiveproperties of FUS-CHOP–expressing MRCLS cells, and clearly
demonstrate that SRC/FAK inhibition may represent an effective
anti-invasive therapeutic strategy.
FAK Expression Correlates with Tumor Aggressiveness in
Sarcoma Tissue Specimens
Next, we aimed to investigate whether enhanced expression of FAK
in sarcoma patients is clinically relevant. To this purpose, we
generated tissue microarrays including FFPE samples from 66
malignant sarcomas and 16 benign/low-malignant sarcoma-related
lesions (Table 1 and Supplementary Table S2), and FAK expression
was analyzed by immunohistochemistry (Figure 5). High levels of
FAK expression were observed in 48.5% (32/66) of malignant
sarcomas. Importantly, high levels of FAK significantly correlated
with tumor grade (P = .004). Interestingly, when FAK expression was
compared between malignant and benign/low-malignant tumors,
high FAK expression was strongly and significantly associated with
malignant sarcomas (P = .009). Finally, although the number of
liposarcomas included in this series was relatively low (10 MRCLS
and 8 liposarcomas of other subtypes), a tendency was observed for
higher expression levels of FAK in MRCLS compared to other
liposarcoma subtypes (P = .09) (Figure 5, Table 1, and Supplemen-
tary Table S2). These results are in line with the tight association
between FUS-CHOP and FAK expression/activity observed in our
MRCLS model.
Inhibition of SRC or FAK Prevents the Invasion of Cancer
Stem Cell (CSC)–Enriched Subpopulations
CSC subpopulations are thought to be responsible for tumor
invasion and metastatic dissemination [39]. We previously showed
that sarcoma models originated from transformed MSCs were able to
grow as floating tumorspheres with enhanced CSC properties [44].
Therefore, we studied whether the inhibition of SRC or FAK could
also be an effective strategy to inhibit the invasive potential of these
subpopulations (Figure 6A). First, we found that tumorsphere
cultures of MSC-4H-GFP cells showed higher levels of phospho-FAK
(Y861 and Y397), phospho-SRC (Y418), and phospho-AKT (S473)
than unselected adherent cultures, while the levels of these
phospho-kinases remained consistently high in MSC-4H-FC adher-
ent and tumorsphere cultures (Figure 6B and Supplementary Figure
S6). As expected, we found that spheroids formed fromMSC-4H-FC
tumorspheres were able to invade 3D collagen matrices more
efficiently than spheroids derived from the fraction of cells unable
to form tumorspheres (Figure 6, C and D and Videos S21-S24).
Notably, dasatinib and PF-573228 were able to reduce invasion in
spheroids-derived from tumorspheres (Figure 6, C and D and Videos
S22-S24) as efficiently as in those derived from the unselected bulk
tumor population (Figure 2C and Supplementary Figure 3C).
Altogether, these results indicate that FAK inhibition prevents
self-renewal and invasive potential of FUS-CHOP–expressing CSCs.
FUS-CHOP–Induced Invasion is Mediated through a RHO/
ROCK-Dependent Mechanism
Based on transcriptomics analysis, we previously found that the
RHO family of GTPases was among the signaling pathways most
significantly altered by FUS-CHOP expression in hMSCs [33].
Given the predominant role of certain members of this family in
tumor invasion, we wondered whether RHO/ROCK signaling could
be involved in SRC/FAK-mediated invasion induced by FUS-CHOP.
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levels of the RHO/ROCK downstream effector MLC2 and its active
phosphorylated form MLC2 (T18/S19) (Figure 7A and
Supplementary Figure S7, A and B). The ratio between phosphor-
ylated and total forms of MLC2 was 3 times higher in MSC-4H-FC
than in MSC-4H-GFP (Figure S7B), indicating that FUS-CHOP
expression may act by regulating both the phosphorylation levels and
the total MLC2 protein expression. This accumulation ofphospho-MLC2 in MSC-4H-FC cells was efficiently inhibited by
increasing doses of the ROCK specific inhibitor RKI-1447 [45]
(Figure 7B and Supplementary Figure S7, C and D). Importantly,
concentrations of RKI-1447 as low as 0.5 μM were able to
completely abolish the invasion of MSC-4H-FC 3D spheroids
(Figure 7C and D and Videos S25-S29) and to significantly reduce
cell extravasation out of the CAM vasculature (Figure 7E) without
having any relevant effect on cell proliferation (Figure 7F). These
Figure 4. Inhibition of SRC or FAK prevents the invasion of the MRCLS cell line 1765-92. (A) Western blotting analysis of the indicated
proteins in 1765-92 cells treated with 1 μM dasatinib or 10 μM PF-573228 for 24 hours. β-Actin levels were used as loading control.
Quantification of three independent experiments is plotted in Supplementary Fig S5. (B and D) Analysis of the effect of dasatinib and
PF-573228 in the invasive properties of 1765-92 cells using 3D spheroid invasion assays. Representative images of the 3D invading
spheroids treated with the indicated inhibitors for 24 hours (B) and quantification of the invasive area of cells treated with dasatinib (C) and
PF-573228 (D) are presented. Scale bars = 200 μm. (E) Cell viability (WST1 assay) measured after treatment of 1765-92 cells with
increasing concentrations of dasatinib (top panel) or PF-573228 (bottom panel) for 24 hours. Error bars represent the SD, and asterisks
indicate statistically significant differences with the control series (*: P b .05; **: P b .01; one-sided Student t test).
Figure 3. Inhibition of FAK prevents the invasion of FUS-CHOP–expressing cells. (A) Western blotting analysis of the indicated proteins in
MSC-4H-FC cells treated with increasing concentrations of PF-573228 for 24 hours. β-Actin levels were used as loading control.
Quantification of three independent experiments is plotted in Supplementary Fig S3. (B and C) Analysis of the effect of increasing
concentrations of PF-573228 on the invasive properties of MSC-4H-FC cells using 3D spheroid invasion assays. Representative images of
the 3D spheroids treated with the indicated concentrations of PF-573228 for 24 hours (B) and quantification of the invasive area (C) are
presented. Scale bars = 200 μm. (D) Representative 3D volume confocal image (60× magnification) of MSC-4H-FC cells pretreated with
10 μM PF-573228 for 24 hours followed by intravenous injection into the chicken embryo CAM vasculature. GFP-positive cells (green),
CAM vasculature labeled using lectin-Dylight649 (violet), and CAM vessel lumen using dextran (red) are shown. The release of
extracellular vesicles/microparticles is indicated in the enlarged area. Scale bars = 5 μm. (E) Quantification of extravasation efficiency of
control and PF-573228-treated MSC-4H-FC cells 24 hours postinjection. (F) Cell viability (WST1 assay) measured after treatment of the
indicated cell lines with increasing concentrations of PF-573228 for 24 or 48 hours. (G) Protein levels of the indicated proteins in
MSC-4H-FC cells transfected with the indicated siRNAs. Quantification is plotted in Supplementary Fig S3. (H and I) Effect of FAK
depletion by siRNA on the invasive properties of MSC-4H-FC cells. Representative images of the 3D invading spheroids after 24 hours (H)
and quantification of the invasive area (I) are presented. Error bars represent the SD, and asterisks indicate statistically significant
differences with the control series (*: P b .05; **: P b .01; one-sided Student t test).
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Table 1. Distribution of Malignant (N = 66) and Benign (N = 16) Sarcoma Cases According to
Their FAK Expression Level Across Categories of the Indicated Patient Characteristics and Tumor
Clinicopathologic Parameters (aMore Comprehensive Description is Presented as Table S2). PValues
are Shown
Low FAK (%) High FAK (%) Total (%) P (Chi-Square)
Malignant cases 34 (51.5) 32 (48.5) 66
Tumor type
Osteosarcoma 4 (11.8) 4 (12.5) 8 (12.1) .047
Ewing sarcoma 2 (5.9) 3 (9.4) 5 (7.6)
Myxoid liposarcoma 7 (20.6) 3 (9.4) 10 (15.2)
Liposarcoma (other subtypes) 8 (23.5) 0 (0) 8 (12.1)
Chondrosarcoma 6 (17.6) 5 (15.6) 11 (16.7)
Synovial sarcoma 3 (8.8) 6 (18.8) 9 (13.6)
Pleomorphic sarcoma 4 (8.8) 7 (21.9) 10 (15.2)
GIST 1 (2.9) 4 (12.5) 5 (7.6)
Total 34 32 66
Tumor grade
1 13 (46.4) 1 (4.4) 14 (27.4) .004
2 8 (28.6) 10 (47.8) 19 (37.3)
3 7 (25) 11 (47.8) 18 (35.3)
Total 28 23 51
Missing 6 9 15
Myxoid liposarcoma vs liposarcoma (other subtypes)
Myxoid liposarcoma 7 (46.7) 3 (100) 10 (55.6) .09
Liposarcoma (other subtypes) 8 (53.3) 0 8 (44.4)
Total 15 3 18
Benign cases 14 (87.5) 2 (12.5) 16
Tumor type
Encondroma 7 (50.0) 0 (0) 7 (43.75) .182
Dermatofibrosarcoma 7 (50.0) 2 (100) 9 (56.35)
Total 14 2 16
Malignant vs benign tumors
Benign 14 (29.2) 2 (5.9) 16 (19.5) .009
Malignant 34 (70.8) 32 (94.1) 66 (80.5)
Total 48 34 82
Figure 5. Immunohistochemical analysis of FAKexpression in sarcomas
FAK staining in sarcoma samples. (A-C) Synovial sarcoma samples showi
1 tumor; B: low FAK–grade 2 tumor; C: high FAK–grade 3 tumor). (D and
other liposarcoma subtypes (D: high FAK–grade 2 MRCLS; E: low FAK–
sample representing that most benign tumor samples displayed low lev
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the phosphorylation of MLC2 is essential to maintain the invasive
properties of FUS-CHOP–expressing cells. In addition, both
dasatinib and PF-573228 were able to prevent MLC2 phosphory-
lation (Figure 7B and Supplementary Figure S7, C and D), thus
reflecting that SRC and FAK are upstream mediators of the
activation of RHO/ROCK signaling.
Altogether, these results indicate that FUS-CHOP–expressing cells
may invade through a mechanism involving the activation of the
SRC/FAK/RHO/ROCK signaling axis.
Discussion
Deregulated SRC/FAK signaling has been extensively related with
enhanced migration and invasion in many types of tumors [5,9]. In
MRCLS, SRC is one of the kinases more frequently activated in both
primary and established cell lines, as well as in patient samples, and
SRC inhibition with dasatinib reduced their migratory and invasive
potential [29,30,41]. In addition, the expression of FUS-CHOP in
sarcoma cell lines increases migration and invasion and enhances the
metastatic potential in these cells [2]. Altogether, these reports suggest
that FUS-CHOP might promote proinvasive phenotypes in MRCLS
through SRC-mediated signaling. Therefore, we studied the
contribution of SRC activation and that of its signaling partner
FAK to sarcoma invasion by using our previously described MRCLS
model, in which FUS-CHOP expression in pretransformed hBMSCs
is able to drive MRCLS formation in vivo [33]. To deeply characterize
the mechanisms involved in FUS-CHOP–induced invasion, we used
3D collagen matrices which are reported to closely mimic the fibrillar
collagen meshworks present in most connective tissues [46] and
therefore represent a relevant in vitro model to reproduce the
microenvironment of many sarcomas. In addition, we also quantifiedamples. Representative images showingdifferent levels of cytoplasmic
ng a correlation of FAK expressionwith tumor grade (A: lowFAK–grade
E)MRCLS samples tend to show higher levels of FAK expression than
grade 1 well-differentiated spindle cell liposarcoma). (F) Encondroma
els of FAK expression. Scale bar = 100 μm.
Figure 6. Inhibition of SRC or FAK activation prevents the invasion of CSC-enriched subpopulations. (A) MSC-4H-FC cells were plated at
low density in tumorsphere medium and let to form tumorspheres for 10 days. Thereafter, tumorspheres and non–tumorsphere-forming
cells were separated and collected. Tumorspheres were disaggregated, and both fractions were allowed to expand to discard nonviable
cells before proceeding with the invasion assays. (B) Protein levels of the indicated proteins in adherent cultures or tumorsphere cultures
of MSC-4H-FC cells allowed to expand in adherence for 16 hours. Quantification is plotted in Supplementary Fig S6. (C and D) Effect of
dasatinib or PF-573228 on the invasive properties of CSC-enriched subpopulations. Representative images of the 3D spheroids of the
non–sphere-forming versus sphere-forming fractions treated or not with the indicated concentrations of dasatinib or PF-573228 for 24
hours (C) and quantification of the invasive area (D) are presented. Error bars represent the SD, and asterisks indicate statistically
significant differences with the control series (**: P b .01; one-sided Student t test).
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found that the expression of FUS-CHOP induced the activation of
SRC and the upregulation/activation of FAK and enhanced invasive
potential. Moreover, using dasatinib, the specific FAK inhibitor
PF-573228, and FAK siRNA, we confirmed the hypothesis that the
activation of SRC/FAK pathway is mediating the invasive properties
induced by FUS-CHOP. Importantly, we show that the inhibition of
SRC/FAK is also able to block the invasive potential of CSC
subpopulations. Treatment with dasatinib or PF-573228 also had a
partial impact on cell proliferation/survival, although these antipro-
liferative effects become relevant at later time points and/or higher
drug concentrations than those that efficiently blocked cell invasion,
thus suggesting that these drugs behave as genuine anti-invasive
agents in sarcoma cells.
SRC inhibition was able to prevent activating phosphorylation of
FAK. However, FAK inhibition did not impede SRC activation.
Given that the inhibition of both kinases efficiently inhibits invasion,
these findings show that FAK is a downstream effector of SRC
activation and its activation is critical for FUS-CHOP–inducedinvasive phenotype. In accordance with this prominent role of FAK,
we found that its expression in sarcoma patient samples significantly
correlated with tumor grade and aggressiveness. These findings about
the role of FAK in invasion and metastasis are in line with previous
studies in other sarcoma subtypes [31,32].
In cancer cells, SRC/FAK pathway activation may induce different
types of invasion with different requirements of Rho GTPases
[9,12,14,19,20]. We found that FUS-CHOP expression induced an
SRC/FAK/RHO/ROCK-dependen t a c cumu l a t i on o f
phospho-MLC2 (T18/S19) which was essential to invade collagen
matrices and extravasate out of the CAM vasculature. In line with a
preponderant role of RHO/ROCK signaling in the ability of
sarcomas to invade, the inhibition of this signaling pathway by
different mechanisms was found to prevent invasion in osteosarcoma
and Ewing sarcoma [47–50]. It is well established that RHO/ROCK
signaling drives the amoeboid type of migration [12,20]. However, it
is also known that certain RHO/ROCK activity is required for the
contractile activity of actomyosin scaffold to retract the cell rear
during the mesenchymal movement [12,51,52]. Historically,
Figure 7. Inhibition of RHO/ROCK signaling prevents the invasion of FUS-CHOP–expressing cells. (A) Western blotting analysis of the
indicated proteins in MSC-4H-GFP, MSC-4H-FC, and MSC-4H-FC-shCHOP cells. (B) Western blotting analysis of the indicated proteins in
MSC-4H-FC cells treated with increasing concentrations of dasatinib, PF-573228, or RKI-1447 for 24 hours. β-Actin levels were used as
loading control. Quantification of three independent experiments is plotted in Supplementary Fig S7. (C and D) Effect of increasing
concentrations of RKI-1447 on the invasive properties of MSC-4H-FC cells using 3D spheroid invasion assays. Representative images of
the 3D invading spheroids treated with the indicated concentrations of dasatinib for 24 hours (C) and quantification of the invasive area (D)
are presented. Scale bars = 200 μm. (E) Quantification of extravasation efficiency of control (DMSO) and RKI-1447 pretreatedMSC-4H-FC
cells 24 hours postinjection into the chicken embryo CAM vasculature. (F) Cell viability (WST1 assay) measured after the treatment of
MSC-4H-FC cells with increasing concentrations of RKI-1447 for 24 hours. Error bars represent the SD, and asterisks indicate statistically
significant differences with the control series (*: P b .05; **: P b .01; one-sided Student t test).
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migrate/invade using an elongated/mesenchymal movement [14].
Nevertheless, a RHO-ROCK-dependent amoeboid mode of invasion
has also been described as a primary invading mechanism for a model
of rat sarcoma cells [53]. In addition, another work showed that
HT1080 fibrosarcoma cells embedded as spheroids in 3D collagen
matrices displayed a transition in morphology from round to
elongated as a function of increasing radial position into the spheroid.
Interestingly, in this collective invasion model, cells presenting
elongated-mesenchymal morphology at the periphery of the spheroids
migrated faster, and their dissemination into the surrounding matrix
was dependent on ROCK/MLC2-driven contractility [21]. In line
with these findings, cells at the periphery of the MRCLS spheroids
displayed an elongated morphology in the 3D invasion assays herein
described, and their mode of invasion was found to be dependent onRHO/ROCK activity. These data suggest that intermediate situations
may exist between mesenchymal and amoeboid models of invasion
which may depend on specific cell determinants and environmental
conditions [16,46].Conclusions
The herein presented data uncover a novel mechanism by which the
fusion oncogene FUS-CHOP actively promotes invasion in myxoid
and round cell liposarcoma through the activation of a SRC/FAK/
RHO/ROCK signaling axis. In addition, we found that FAK
expression significantly correlates with tumor aggressiveness and
advanced disease stage in sarcoma patient samples. Therefore, the
inhibition of this signaling could represent a potential antimetastatic
therapeutic strategy for this type of tumors.
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